GlassScriptPhysician profile
Naveen K Gowda
NPI 1063544047
$723.61
in general payments reported to CMS, 2019-2025
10 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $19.16 · 2021: $19.35 · 2022: $26.25 · 2024: $116 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $227.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $170.00 | 2019 | |
| Angiodynamics, INC. | $132.17 | 2024-2025 | Alphavac |
| Bard Peripheral Vascular, INC. | $115.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.06 | 2025 | |
| Boston Scientific Corporation | $64.79 | 2019 | |
| Ekos Corporation | $41.28 | 2019 | |
| Abbott Laboratories | $40.42 | 2019 | |
| Imperative Care, INC | $26.25 | 2022 | |
| Inari Medical, INC. | $19.35 | 2021 | |
| Penumbra, INC. | $19.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.